RT Book, Section
A1 Curry, Jonathan L.
A1 Chu, Emily Y.
A1 Tetzlaff, Michael T.
A2 Barnhill, Raymond L.
A2 Crowson, A. Neil
A2 Magro, Cynthia M.
A2 Piepkorn, Michael W.
A2 Kutzner, Heinz
A2 Desman, Garrett T.
SR Print(0)
ID 1178398187
T1 Cutaneous Drug Eruptions
T2 Barnhill's Dermatopathology, 4e
YR 2020
FD 2020
PB McGraw Hill Education
PP New York, NY
SN 9780071828222
LK dermatology.mhmedical.com/content.aspx?aid=1178398187
RD 2024/04/20
AB Advances  in  molecular  techniques  and  the  ability  to  perform  deep  cancer  phenotyping  has  ushered  in  the  era  of  precision  cancer  medicine.1  The  field  of  medical  oncology  has  witnessed  a  paradigm  shift  in  the  treatment  of  cancer  with  targeted  cancer  therapy  with  small  molecule  inhibitors  (Nibs)  and  monoclonal  antibodies  (Mabs).  Given  the  frequency  of  adverse  cutaneous  reactions  encountered  from  Nibs  and  Mabs,  the  field  of  dermatopathology  has  now  entered  an  era  of  “oncologic  dermatopathology.”  As  a  result,  increasingly  dermatopathologists  are  confronted  with  a  diverse  array  of  adverse  cutaneous  reactions  developing  in  patients  undergoing  novel  anticancer  treatments.  Knowledge  of  the  clinical  features  of  these  adverse  reactions  will  aid  dermatopathologists  in  making  accurate  diagnoses.